"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology Cancer Center Sugar Land conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 34 clinical trials were completed, i.e. on average, 242.9% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 10 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology Cancer Center Sugar Land" #1 sponsor was "Radiation Therapy Oncology Group" with 16 trials, followed by "US Oncology Research" with 11 trials sponsored, "National Cancer Institute (NCI)" with 4 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored and "NRG Oncology" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology Cancer Center Sugar Land" #1 collaborator was "National Cancer Institute (NCI)" with 24 trials as a collaborator, "NRG Oncology" with 20 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator, "Radiation Therapy Oncology Group" with 4 trials as a collaborator and "Pfizer" with 3 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology Cancer Center Sugar Land" are "Breast Cancer" (9 trials), "Prostate Cancer" (8 trials), "Metastatic Breast Cancer" (5 trials), "Lung Cancer" (4 trials) and "Cognitive/Functional Effects" (2 trials). Many other conditions were trialed in "Texas Oncology Cancer Center Sugar Land" in a lesser frequency.

Most popular intervention types in "Texas Oncology Cancer Center Sugar Land" are "Drug" (41 trials), "Radiation" (25 trials), "Other" (12 trials), "Biological" (7 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (7 trials), "Laboratory Biomarker Analysis" (7 trials), "Paclitaxel" (6 trials), "Bevacizumab" (4 trials) and "Placebo" (4 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology Cancer Center Sugar Land" are 29 trials for "All" genders, 16 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology Cancer Center Sugar Land". undefined are not yet recruiting, 3 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Texas Oncology Cancer Center Sugar Land, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology Cancer Center Sugar Land, 1 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".